Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics. Biotechs are...
Covered in this story
Analyst targets on Veeva Systems
- Stifel: $282 → $300 by Aug 2027 · Buy via Investing.com
- Stifel: $238 → $275 by Aug 2027 · Buy via Investing.com
- Guggenheim: $185 → $232 by Jul 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $VEEV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Veeva Systems →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.